Skip to main content
Article
Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma.
Journal for ImmunoTherapy of Cancer (2020)
  • Brendan Curti, Providence Portland Medical Center
  • Marka Crittenden, Providence Cancer Institute, Earle A Chiles Research Institute
  • Steven K Seung, Division of Radiation Oncology
  • Christopher B Fountain, Providence Portland Medical Center
  • Roxanne Payne, Providence Portland Medical Center
  • ShuChing Chang, Medical Data Research Center
  • Jessica Fleser, Providence Portland Medical Center
  • Kimberly Phillips, Providence Portland Medical Center
  • Ian Malkasian, Providence Portland Medical Center
  • Lyn B Dobrunick, Providence Portland Medical Center
  • Walter J Urba, Providence Portland Medical Center
Publication Date
May 1, 2020
DOI
10.1136/JITC-2020-000773
Citation Information
Brendan Curti, Marka Crittenden, Steven K Seung, Christopher B Fountain, et al.. "Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma." Journal for ImmunoTherapy of Cancer Vol. 8 Iss. 1 (2020) p. 1177
Available at: http://works.bepress.com/walter-urba/285/